Abstracts tagged "Hydroxychloroquine"

Abstract Number: 2896 • 2018 ACR/ARHP Annual Meeting
Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
April Jorge¹, Na Lu^2,3, Eric C. Sayre³, Hamid Tavakoli⁴, Natalie McCormick⁵, John M. Esdaile^3,6, Mary DeVera⁵, Hyon K. Choi¹ and J. Antonio Avina-Zubieta⁷, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE. Use of this medication has previously been associated with a substantial survival benefit among SLE…
Abstract Number: 2897 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy
Michelle Petri¹, Marwa Elkhalifa², Daniel Goldman¹, Laurence S Magder³ and Mandeep Singh⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ⁴Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy after 10 years or more of use is more frequent than previously appreciated. This led to new ophthalmology guidelines that changed…
Abstract Number: 2112 • 2018 ACR/ARHP Annual Meeting
IFN-Gene Expression Is Elevated in Subacute Cutaneous Lupus Erythematous and DLE and Decreases with Treatment in DLE
Stephanie Lazar¹, Rajaie Namas², Celine C. Berthier³ and Michelle Kahlenberg⁴, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patients with SLE have increased type I IFN-regulated gene expression in peripheral blood, which has been correlated with systemic disease activity. IFN-regulated gene expression…
Abstract Number: 2140 • 2018 ACR/ARHP Annual Meeting
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Rheumatoid Arthritis: A Retrospective Study
Alisha Gupta¹, Aditya Joshi¹, Omar Saleem¹, Mary Chester-Wasko² and Tarun S. Sharma³, ¹Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a derivative of quinidine, a class 1a anti-arrhythmic agent used to prevent ventricular arrhythmias and recurrent atrial fibrillation (AFib). AFib occurs…
Abstract Number: 2146 • 2018 ACR/ARHP Annual Meeting
A Meta-Analysis of the Prevalence and Risk Factors for Retinal Toxicity in Rheumatologic Patients on Hydroxychloroquine Therapy
Amanda Worme¹, Leonardo Tamariz², Ana Palacio², Zsuzsanna Nemeth³ and Mathew Farbman⁴, ¹Internal Medicine, University of Miami Miller School of Medicine at Holy Cross Hospital, Fort Lauderdale, FL, ²Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, ³Health Informatics, University of Miami Miller School of Medicine, Miami, FL, ⁴Rheumatology, University of Miami Miller School of Medicine at Holy Cross Hospital, Fort Lauderdale, FL
Background/Purpose: HCQ is one of the most common DMARD(s) used in treatment of several rheumatologic diseases, including RA and SLE. Although rare, retinal toxicity remains…
Abstract Number: 2179 • 2018 ACR/ARHP Annual Meeting
Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study
Ksenia Gukova¹, John M. Esdaile², Hamid Tavakoli³ and J. Antonio Avina-Zubieta^1,2, ¹Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Antimalarial drugs (AM) are commonly used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). AM can be associated with retinal toxicity that…
Abstract Number: 2348 • 2018 ACR/ARHP Annual Meeting
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Maria A. Lopez-Olivo¹, Jude K. A. des Bordes¹, Gregory Pratt² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of…
Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Kiyo Ueeda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…
Abstract Number: 2670 • 2018 ACR/ARHP Annual Meeting
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus: A Retrospective Study
Alisha Gupta¹, Aditya Joshi¹, Mary Chester-Wasko² and Tarun S. Sharma³, ¹Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a derivative of quinidine, a class 1a anti-arrhythmic agent used to prevent ventricular arrhythmias and recurrent atrial fibrillation (AFib). AFib occurs…
Abstract Number: 8L • 2017 ACR/ARHP Annual Meeting
Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
Dilpreet Singh¹, Leila Muhieddine², Douglas Einstadter³ and Stanley Ballou⁴, ¹Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ²Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ³Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ⁴Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of chronic rheumatic diseases. Its long-standing use has been associated with retinopathy in a daily and…
Abstract Number: 1651 • 2017 ACR/ARHP Annual Meeting
Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity
Anna Viola Taulaigo¹, Maria Francisca Moraes-Fontes¹, Eunice Patarata², Sara Guerreiro Castro² and Arnaldo Dias-Santos³, ¹Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, ²Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (CHLC), Lisbon, Portugal, Lisbon, Portugal, ³Serviço de Oftalmologia, Hospital de Santo António dos Capuchos, CHLC, Lisbon, Portugal, Lisbon, Portugal
Background/Purpose: Despite effectiveness and favourable safety profile, antimalarials have the potential to cause irreversible macular retinopathy and vision loss. Screening methods still vary among clinicians…
Abstract Number: 1964 • 2017 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review
April Jorge¹, Sharan K. Rai² and Hyon K. Choi², ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. While generally well-tolerated and…
Abstract Number: 2035 • 2017 ACR/ARHP Annual Meeting
Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
Sahil Koppikar¹ and Henry Averns², ¹Department of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Private Practice, Kingston, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is used widely for the treatment of inflammatory arthritides and systemic lupus erythematosus. Recent publications have shown that HCQ toxicity is not…
Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Hua Chen¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].